Impact of cardiometabolic risk factors on major cardiovascular events in patients with familial combined hyperlipidemia

Circulation Journal

Volumn 77, Issue 1, 2013, Pages 163-168

  Skoumas, Ioannis ^a   Masoura, Constantina ^a   Aznaouridis, Konstantinos ^a   Metaxa, Vassiliki ^a   Tsokanis, Athanassios ^a   Papadimitriou, Lambros ^a   Tousoulis, Dimitrios ^a   Pitsavos, Christos ^a   Stefanadis, Christodoulos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Cardiovascular risk; Familial combined hyperlipidemia; Hypertension; Inherited dyslipidemia; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FAMILIAL HYPERLIPEMIA; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

EID: 84871695074     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0320     Document Type: Article

References (25)

1. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: An up-date; Atherosclerosis and Metabolic Diseases Study Group. Vasc Health Risk Manag 2007; 3: 877-886.
2. Veerkamp M, de Graaf J, Bredie S, Hendriks J, Demacker P, Stalenhoef AF. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: Results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002; 22: 274-278.
3. Voors-Pette C, de Bruin TW. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis 2001; 157: 481-489.
4. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-2607.
5. Keulen ET, Voors-Pette C, de Bruin TW. Familial dyslipidemic hypertension syndrome: Familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 2001; 14: 357-363.
6. Skoumas I, Masoura C, Pitsavos C, Tousoulis D, Papadimitriou L, Aznaouridis K, et al. Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Int J Cardiol 2007; 121: 178-183.
7. Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108: 519-523.
8. Wiesbauer F, Blessberger H, Azar D, Province MA, Pankow JS, Eckfeldt JH, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur Heart J 2009; 30: 1073-1079.
9. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101: 2777-2782.
10. Skoumas J, Papadimitriou L, Pitsavos C, Masoura C, Giotsas N, Chrysohoou C, et al. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia. Metabolism 2007; 56: 135-141.
11. Pitsavos C, Skoumas I, Masoura C, Aznaouridis K, Papadimitriou L, Chrysohoou C, et al. Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia. Atherosclerosis 2008; 19: 402-407.
12. Gaddi A, Galetti C, Pauciullo P, Arca M. Familial combined hyperlipoproteinemia: Experts' panel position on diagnostic criteria for clinical practice: Committee of experts of the Atherosclerosis and Dysmetabolic Disorders, Study Group. Nutr Metab Cardiovasc Dis 1999; 9: 304-311.
13. de Graaf J, van der Vleuten G, Stalenhoef AF. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 2004; 4: 229-240.
14. Aguilar Salinas C, Zamora M, Gomez-Diaz R, Mehta R, Gómez Pérez FJ, Rull JA. Familial combined hyperlipidemia: Controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med 2004; 2: 203-209.
15. Assmann G, Schulte H. Relation of HDL-cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster Study. Am J Cardiol 1992; 70: 733-737.
16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010; 33 (Suppl 1): S11-S61.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
19. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II: Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-1568.
20. Shoulders CC, Naoumova RP. USF1 implicated in the aetiology of familial combined hyperlipidaemia and the metabolic syndrome. Trends Mol Med 2004; 10: 362-365.
21. Shoulders CC, Johnes EL, Naoumona RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 2004; 13: 149-160.
22. Lee JC, Weissglas-Volkov D, Kyttälä M, Sinsheimer JS, Jokiaho A, de Bruin TW, et al. USF1 contributes to high serum lipid levels in Dutch FCHL families and U.S. whites with coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27: 2222-2227.
23. Ascaso JF, Lorente R, Merchante A, Real JT, Priego A, Carmena R. Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease. Am J Cardiol 1997; 80: 1484-1487.
24. Cabre A, Lazaro I, Cofan M, Jarauta E, Plana N, Garcia-Otin AL, et al. FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res 2010; 51: 1173-1178.
25. Hsu BG, Chen YC, Lee RP, Lee CC, Lee CJ, Wang JH. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J 2010; 74: 327-331.